Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue

S. L. Cohn, T. J. Moss, M. Hoover, H. M. Katzenstein, Paul Haut, E. R. Morgan, A. A. Green, M. Kletzel

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

A single institutional pilot study was conducted in which 12 poor-risk neuroblastoma (NB) patients were uniformly treated with multi-agent induction chemotherapy followed by myeloablative consolidation chemotherapy and unpurged peripheral blood stem cell (PBSC) rescue. In addition to using standard criteria for evaluating response to induction chemotherapy, tumor cell contamination of the peripheral blood and/or bone marrow was analyzed in seven patients by immunocytology using a panel of five anti-NB monoclonal antibodies. Seven patients had morphologic evidence of bone marrow disease at the time of diagnosis, and two additional patients had tumor cells detected in bone marrow samples by immunocytology prior to the second cycle of chemotherapy. After three cycles of chemotherapy, two of the 12 patients continued to have evidence of bone marrow disease. Samples from 29 PBSC harvests collected from nine patients were also analyzed for the presence of contaminating tumor cells by immunocytology. In each case, the stem cells were found to be free of tumor. Eleven of the 12 patients underwent myeloablative therapy and PBSC rescue; five patients remain alive without disease progression, 28+ to 53+ months from diagnosis, and six patients have developed recurrent disease. We conclude that PBSCs can be successfully harvested from children with NB, and used for hematopoietic reconstitution following myeloablative chemotherapy. However, more effective therapy for poor-risk NB patients is still urgently needed.

Original languageEnglish (US)
Pages (from-to)543-551
Number of pages9
JournalBone Marrow Transplantation
Volume20
Issue number7
StatePublished - Oct 1 1997
Externally publishedYes

Fingerprint

Neuroblastoma
Drug Therapy
Bone Marrow Diseases
Therapeutics
Induction Chemotherapy
Neoplasms
Bone Marrow
Consolidation Chemotherapy
Peripheral Blood Stem Cells
Disease Progression
Stem Cells
Monoclonal Antibodies

Keywords

  • Immunocytology
  • Neuroblastoma
  • Peripheral blood stem cells
  • Tumor cell contamination

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Cohn, S. L., Moss, T. J., Hoover, M., Katzenstein, H. M., Haut, P., Morgan, E. R., ... Kletzel, M. (1997). Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. Bone Marrow Transplantation, 20(7), 543-551.

Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. / Cohn, S. L.; Moss, T. J.; Hoover, M.; Katzenstein, H. M.; Haut, Paul; Morgan, E. R.; Green, A. A.; Kletzel, M.

In: Bone Marrow Transplantation, Vol. 20, No. 7, 01.10.1997, p. 543-551.

Research output: Contribution to journalArticle

Cohn, SL, Moss, TJ, Hoover, M, Katzenstein, HM, Haut, P, Morgan, ER, Green, AA & Kletzel, M 1997, 'Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue', Bone Marrow Transplantation, vol. 20, no. 7, pp. 543-551.
Cohn, S. L. ; Moss, T. J. ; Hoover, M. ; Katzenstein, H. M. ; Haut, Paul ; Morgan, E. R. ; Green, A. A. ; Kletzel, M. / Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. In: Bone Marrow Transplantation. 1997 ; Vol. 20, No. 7. pp. 543-551.
@article{c86ba38d230d4cf49da75e719d0293c9,
title = "Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue",
abstract = "A single institutional pilot study was conducted in which 12 poor-risk neuroblastoma (NB) patients were uniformly treated with multi-agent induction chemotherapy followed by myeloablative consolidation chemotherapy and unpurged peripheral blood stem cell (PBSC) rescue. In addition to using standard criteria for evaluating response to induction chemotherapy, tumor cell contamination of the peripheral blood and/or bone marrow was analyzed in seven patients by immunocytology using a panel of five anti-NB monoclonal antibodies. Seven patients had morphologic evidence of bone marrow disease at the time of diagnosis, and two additional patients had tumor cells detected in bone marrow samples by immunocytology prior to the second cycle of chemotherapy. After three cycles of chemotherapy, two of the 12 patients continued to have evidence of bone marrow disease. Samples from 29 PBSC harvests collected from nine patients were also analyzed for the presence of contaminating tumor cells by immunocytology. In each case, the stem cells were found to be free of tumor. Eleven of the 12 patients underwent myeloablative therapy and PBSC rescue; five patients remain alive without disease progression, 28+ to 53+ months from diagnosis, and six patients have developed recurrent disease. We conclude that PBSCs can be successfully harvested from children with NB, and used for hematopoietic reconstitution following myeloablative chemotherapy. However, more effective therapy for poor-risk NB patients is still urgently needed.",
keywords = "Immunocytology, Neuroblastoma, Peripheral blood stem cells, Tumor cell contamination",
author = "Cohn, {S. L.} and Moss, {T. J.} and M. Hoover and Katzenstein, {H. M.} and Paul Haut and Morgan, {E. R.} and Green, {A. A.} and M. Kletzel",
year = "1997",
month = "10",
day = "1",
language = "English (US)",
volume = "20",
pages = "543--551",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue

AU - Cohn, S. L.

AU - Moss, T. J.

AU - Hoover, M.

AU - Katzenstein, H. M.

AU - Haut, Paul

AU - Morgan, E. R.

AU - Green, A. A.

AU - Kletzel, M.

PY - 1997/10/1

Y1 - 1997/10/1

N2 - A single institutional pilot study was conducted in which 12 poor-risk neuroblastoma (NB) patients were uniformly treated with multi-agent induction chemotherapy followed by myeloablative consolidation chemotherapy and unpurged peripheral blood stem cell (PBSC) rescue. In addition to using standard criteria for evaluating response to induction chemotherapy, tumor cell contamination of the peripheral blood and/or bone marrow was analyzed in seven patients by immunocytology using a panel of five anti-NB monoclonal antibodies. Seven patients had morphologic evidence of bone marrow disease at the time of diagnosis, and two additional patients had tumor cells detected in bone marrow samples by immunocytology prior to the second cycle of chemotherapy. After three cycles of chemotherapy, two of the 12 patients continued to have evidence of bone marrow disease. Samples from 29 PBSC harvests collected from nine patients were also analyzed for the presence of contaminating tumor cells by immunocytology. In each case, the stem cells were found to be free of tumor. Eleven of the 12 patients underwent myeloablative therapy and PBSC rescue; five patients remain alive without disease progression, 28+ to 53+ months from diagnosis, and six patients have developed recurrent disease. We conclude that PBSCs can be successfully harvested from children with NB, and used for hematopoietic reconstitution following myeloablative chemotherapy. However, more effective therapy for poor-risk NB patients is still urgently needed.

AB - A single institutional pilot study was conducted in which 12 poor-risk neuroblastoma (NB) patients were uniformly treated with multi-agent induction chemotherapy followed by myeloablative consolidation chemotherapy and unpurged peripheral blood stem cell (PBSC) rescue. In addition to using standard criteria for evaluating response to induction chemotherapy, tumor cell contamination of the peripheral blood and/or bone marrow was analyzed in seven patients by immunocytology using a panel of five anti-NB monoclonal antibodies. Seven patients had morphologic evidence of bone marrow disease at the time of diagnosis, and two additional patients had tumor cells detected in bone marrow samples by immunocytology prior to the second cycle of chemotherapy. After three cycles of chemotherapy, two of the 12 patients continued to have evidence of bone marrow disease. Samples from 29 PBSC harvests collected from nine patients were also analyzed for the presence of contaminating tumor cells by immunocytology. In each case, the stem cells were found to be free of tumor. Eleven of the 12 patients underwent myeloablative therapy and PBSC rescue; five patients remain alive without disease progression, 28+ to 53+ months from diagnosis, and six patients have developed recurrent disease. We conclude that PBSCs can be successfully harvested from children with NB, and used for hematopoietic reconstitution following myeloablative chemotherapy. However, more effective therapy for poor-risk NB patients is still urgently needed.

KW - Immunocytology

KW - Neuroblastoma

KW - Peripheral blood stem cells

KW - Tumor cell contamination

UR - http://www.scopus.com/inward/record.url?scp=0030716926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030716926&partnerID=8YFLogxK

M3 - Article

C2 - 9337055

AN - SCOPUS:0030716926

VL - 20

SP - 543

EP - 551

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -